149 related articles for article (PubMed ID: 26000289)
1. Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics.
Zhan F; Zangari M; Qiu L
Biomed Res Int; 2015; 2015():384575. PubMed ID: 26000289
[No Abstract] [Full Text] [Related]
2. Mechanisms of drug resistance in hematologic malignancies.
Dalton WS
Semin Hematol; 1997 Oct; 34(4 Suppl 5):3-8. PubMed ID: 9408955
[TBL] [Abstract][Full Text] [Related]
3. Drug resistance.
Tomasetti C
Adv Exp Med Biol; 2014; 844():303-16. PubMed ID: 25480648
[TBL] [Abstract][Full Text] [Related]
4. Development of expression-based biomarkers of Dasatinib response in hematologic malignancies.
Akre MK; Mitra A; Wang W; Myers CL; Van Ness B
Blood Cancer J; 2017 Dec; 7(12):652. PubMed ID: 29242603
[No Abstract] [Full Text] [Related]
5. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
Usui N
Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
[No Abstract] [Full Text] [Related]
6. Drug resistance in hematologic malignancies.
Dalton W
Clin Adv Hematol Oncol; 2005 Apr; 3(4):267-8. PubMed ID: 16166998
[No Abstract] [Full Text] [Related]
7. All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi).
Sacchi S; Russo D; Avvisati G; Dastoli G; Lazzarino M; Pelicci PG; Bonora MR; Visani G; Grassi C; Iacona I; Luzzi L; Vanzanelli P
Haematologica; 1997; 82(1):106-21. PubMed ID: 9107096
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance-related microRNAs in hematological malignancies: translating basic evidence into therapeutic strategies.
Xie L; Jing R; Qi J; Lin Z; Ju S
Blood Rev; 2015 Jan; 29(1):33-44. PubMed ID: 25263425
[TBL] [Abstract][Full Text] [Related]
9. EPHA3 as a novel therapeutic target in the hematological malignancies.
Keane N; Freeman C; Swords R; Giles FJ
Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
[TBL] [Abstract][Full Text] [Related]
10. The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies.
Zivny J; Klener P; Pytlik R; Andera L
Curr Pharm Des; 2010 Jan; 16(1):11-33. PubMed ID: 20214615
[TBL] [Abstract][Full Text] [Related]
11. [Hematologic Malignancies/Pediatric Malignancies. Roles of Drugs Approved as New Agents and as Additional Indications for Relapse or Refractory Hematologic Malignancies].
Usui N
Gan To Kagaku Ryoho; 2016 May; 43(5):528-9. PubMed ID: 27344679
[No Abstract] [Full Text] [Related]
12. Cancer associated fibroblasts in hematological malignancies.
Raffaghello L; Vacca A; Pistoia V; Ribatti D
Oncotarget; 2015 Feb; 6(5):2589-603. PubMed ID: 25474039
[TBL] [Abstract][Full Text] [Related]
13. The role of protein kinase C-alpha in hematologic malignancies.
Lahn M; Sundell K; Köhler G
Acta Haematol; 2006; 115(1-2):1-8. PubMed ID: 16424642
[TBL] [Abstract][Full Text] [Related]
14. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
[TBL] [Abstract][Full Text] [Related]
15. Emerging targets for hematological malignancies.
Cilloni D; Frassoni F; Saglio G
Curr Opin Drug Discov Devel; 2010 Sep; 13(5):548-58. PubMed ID: 20812146
[TBL] [Abstract][Full Text] [Related]
16. [Hematologic Malignancies/Pediatric Malignancies New Therapeutic Strategy for Hematologic Malignancies].
Usui N
Gan To Kagaku Ryoho; 2018 May; 45(5):793-794. PubMed ID: 30026439
[No Abstract] [Full Text] [Related]
17. Editorial [hot topic: Therapeutic targeting of the sphingolipid "biostat" in hematologic malignancies (guest editors: Thomas P. Loughran and Hong-Gang Wang)].
Loughran TP; Wang HG
Anticancer Agents Med Chem; 2011 Nov; 11(9):780-1. PubMed ID: 22023044
[No Abstract] [Full Text] [Related]
18. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
Yee KW; Hagey A; Verstovsek S; Cortes J; Garcia-Manero G; O'Brien SM; Faderl S; Thomas D; Wierda W; Kornblau S; Ferrajoli A; Albitar M; McKeegan E; Grimm DR; Mueller T; Holley-Shanks RR; Sahelijo L; Gordon GB; Kantarjian HM; Giles FJ
Clin Cancer Res; 2005 Sep; 11(18):6615-24. PubMed ID: 16166440
[TBL] [Abstract][Full Text] [Related]
19. [Research on demethylation therapy for hematology malignancy].
Shen JZ; Zhou HR
Zhonghua Nei Ke Za Zhi; 2006 May; 45(5):355-6. PubMed ID: 16780731
[No Abstract] [Full Text] [Related]
20. [The immunology laboratory in malignant blood diseases].
López Berges MC; Vidriales B; Ocqueteau M; Orfao A
Sangre (Barc); 1996 Aug; 41(4):281-8. PubMed ID: 8984669
[No Abstract] [Full Text] [Related]
[Next] [New Search]
